Elutia completes $11M SimpliDerm sale to fund future launch
Elutia divested its SimpliDerm business via a deal valued at up to $11 million, bringing in immediate non-dilutive capital to support the commercial launch of its key antibiotic-eluting biomatrix, NXT-41x, in 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day